down arrow

Newland Pharmaceutical Co., Ltd.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000065K2
CNY
12.26
-5.44 (-30.73%)

Dec 05

SHE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Newland Pharmaceutical Co., Ltd.
Why is Newland Pharmaceutical Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 12.40% and Operating profit at 8.33% over the last 5 years
2
With a fall in Net Sales of -34.84%, the company declared Very Negative results in Jun 25
  • NET SALES(Q) At CNY 137.19 MM has Fallen at -34.84%
  • NET PROFIT(Q) At CNY 21.36 MM has Fallen at -61.39%
  • RAW MATERIAL COST(Y) Grown by 22.76% (YoY)
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Newland Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Newland Pharmaceutical Co., Ltd.
-100.0%
0.60
59.59%
China Shanghai Composite
15.19%
1.01
15.10%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
12.40%
EBIT Growth (5y)
8.33%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.49
Sales to Capital Employed (avg)
0.44
Tax Ratio
13.70%
Dividend Payout Ratio
46.09%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.84%
ROE (avg)
10.96%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
7
Industry P/E
Price to Book Value
0.62
EV to EBIT
1.97
EV to EBITDA
1.46
EV to Capital Employed
0.32
EV to Sales
0.40
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
16.10%
ROE (Latest)
9.34%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company
Icon
NO KEY POSITIVE TRIGGERS
-24What is not working for the Company
NET SALES(Q)

At CNY 137.19 MM has Fallen at -34.84%

NET PROFIT(Q)

At CNY 21.36 MM has Fallen at -61.39%

RAW MATERIAL COST(Y)

Grown by 22.76% (YoY

DEBT-EQUITY RATIO (HY)

Highest at -43.4 %

OPERATING PROFIT(Q)

Lowest at CNY 33.43 MM

PRE-TAX PROFIT(Q)

Lowest at CNY 22.48 MM

EPS(Q)

Lowest at CNY 0.05

Here's what is not working for Newland Pharmaceutical Co., Ltd.
Net Sales
At CNY 137.19 MM has Fallen at -34.84%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely negative

Net Sales (CNY MM)

Pre-Tax Profit
At CNY 22.48 MM has Fallen at -66.98%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CNY MM)

Net Profit
At CNY 21.36 MM has Fallen at -61.39%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (CNY MM)

Net Sales
Lowest at CNY 137.19 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)

Operating Profit
Lowest at CNY 33.43 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (CNY MM)

Pre-Tax Profit
Lowest at CNY 22.48 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit
Lowest at CNY 21.36 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (CNY MM)

EPS
Lowest at CNY 0.05
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (CNY)

Debt-Equity Ratio
Highest at -43.4 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 22.76% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."